Developing a Candidate Ebola Vaccine

Developing a Candidate Ebola Vaccine


Ebola virus was discovered in 1976 after two deadly outbreaks in Central
Africa. Since then, Ebola viruses have
emerged periodically in this and other regions of the
continent. In 2014, a large outbreak of Ebola struck
Guinea, Liberia, and neighboring countries in West Africa,
killing thousands of people and threatening to destabilize these
developing nations. “We’re in the middle of a cataclysmic
outbreak in West Africa.” Dr. Anthony Fauci is the
director of the National Institute of Allergy and Infectious Diseases, or NIAID, where scientists are
spearheading efforts to develop Ebola vaccines and treatments as
quickly as possible. “As this epidemic now has become most extraordinary in its historic scope, it is entirely conceivable that, despite the infusion of resources for
classical infection control, with identification,
isolation, contact tracing, we may actually need a safe and effective
vaccine to actually end this epidemic in West Africa.” Several
Ebola vaccine candidates are undergoing testing in people after
proving to be effective in animals. One of these products is an experimental
vaccine developed by researchers at NIAID’s Vaccine
Research Center. It uses a chimpanzee cold virus to
deliver a small piece of Ebola genetic material to the body. Dr. Nancy Sullivan is one of the
researchers developing the vaccine. “That piece of Ebola virus mimics the protein that’s on the outside of the
virus, so when the vaccine is given, it fools the person’s immune system into
thinking that it’s infected, but in fact it’s not
infected. The vaccine is not made out of virus.
It just contains a very small piece of the virus.” NIAID has partnered with
pharmaceutical company GlaxoSmithKline to advance the vaccine through clinical
trials, beginning with Phase 1 safety testing at the National Institutes of
Health and expanding to additional sites in the
United States and abroad. Researchers hope to advance the
vaccine through all three phases of clinical testing to ensure that it is both safe and
effective in preventing Ebola infection. NIAID will continue to work
with industry and government partners to accelerate efforts to develop Ebola
vaccines and treatments in a way that is both scientifically and ethically sound. “When you have a trial of a vaccine, the first thing you show in Phase 1 is
safety. If it’s safe, then you want to show that it induces the
kind of response that you would predict would be protective. Once you establish that initial safety,
then you go into a much larger trial that defines the efficacy: Does it really
work under conditions of the disease
outbreak? So it’s a multistep process that’s tried and true and has proven to be effective historically with many vaccines.”

2 Replies to “Developing a Candidate Ebola Vaccine”

  1. Lord have mercy, we dont need vaccines, all we need to do is destroy all of Bill and Melinda Gates bio weapon labs, starting with the one smack dab in the heart of Sierra Leonne. This is where the outbreak started and that bio lab was running out of the government hospital, being the only pace testing for ebola.. seems rather fishy to me

Add a Comment

Your email address will not be published. Required fields are marked *